These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34854196)

  • 41. Pruritic rash of the hands and feet.
    Levine N
    Geriatrics; 1997 Jun; 52(6):29. PubMed ID: 9194787
    [No Abstract]   [Full Text] [Related]  

  • 42. Transcriptomic response of peripheral blood mononuclear cells to dupilumab in a 65-year-old patient with bullous pemphigoid.
    Li ML; Hong YK; Lin YC; Natsuga K; Ujiie H; Izumi K; Iwata H; Hsu CK
    Clin Exp Dermatol; 2023 Dec; 49(1):73-74. PubMed ID: 37650504
    [No Abstract]   [Full Text] [Related]  

  • 43. Successful dupilumab treatment in bullous pemphigoid complicated with subacute hematogenous disseminated tuberculosis: A case report.
    Dong Q; Zheng R; He Z; Xi Y
    Skin Res Technol; 2024 Jul; 30(7):e13847. PubMed ID: 38995310
    [No Abstract]   [Full Text] [Related]  

  • 44. Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: A multicenter retrospective review.
    Learned C; Cohen SR; Cunningham K; Alsukait S; Santiago S; Lu J; Rothe M; Nichols A; Rosmarin D
    J Am Acad Dermatol; 2023 Aug; 89(2):378-382. PubMed ID: 37115111
    [No Abstract]   [Full Text] [Related]  

  • 45. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab.
    Bruni M; Moar A; Schena D; Girolomoni G
    Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-bullous lesions as the first manifestation of bullous pemphigoid: A retrospective analysis of 181 cases.
    Zhang Y; Luo Y; Han Y; Tian R; Li W; Yao X
    J Dermatol; 2017 Jul; 44(7):742-746. PubMed ID: 28256743
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reply to: 'Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab' by Baffa et al.
    Sun L; Brazão C; Mancha D; Soares-de-Almeida L; Filipe P
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):e578-e580. PubMed ID: 36681888
    [No Abstract]   [Full Text] [Related]  

  • 48. Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid.
    Manzo Margiotta F; Fidanzi C; Bevilacqua M; Janowska A; Romanelli M; Manni E
    Skin Res Technol; 2023 Oct; 29(10):e13488. PubMed ID: 37881049
    [No Abstract]   [Full Text] [Related]  

  • 49. Prevalence and predictors of pruritus in pemphigus compared with bullous pemphigoid: A cross-sectional study.
    Rolader R; Daugherty LN; Liu Y; Feldman RJ
    J Am Acad Dermatol; 2020 Jul; 83(1):251-254. PubMed ID: 31962093
    [No Abstract]   [Full Text] [Related]  

  • 50. Exacerbation of clinical manifestations of bullous pemphigoid after treatment with dupilumab.
    Mariotti EB; Corrà A; Aimo C; Ruffo di Calabria V; Quintarelli L; Verdelli A; Caproni M
    Clin Exp Dermatol; 2024 Mar; 49(4):399-400. PubMed ID: 38011325
    [No Abstract]   [Full Text] [Related]  

  • 51. Interleukin 4 and interleukin 13 inhibition: A promising therapeutic approach in bullous pemphigoid.
    Geller S
    J Am Acad Dermatol; 2020 Jul; 83(1):37-38. PubMed ID: 32179081
    [No Abstract]   [Full Text] [Related]  

  • 52. Bullous pemphigoid: Comparing the prevalence and severity of itch and pain.
    Dan J; Sprow G; Diaz D; Kodali N; Patel J; Vazquez T; Werth VP
    J Am Acad Dermatol; 2023 Jul; 89(1):159-160. PubMed ID: 36842504
    [No Abstract]   [Full Text] [Related]  

  • 53. Pruritus and Tense Bullae After Discontinuation of Pembrolizumab in a Patient With Renal Cell Carcinoma.
    Bieber AK; Yin L; Lo Sicco K
    JAMA; 2020 Oct; 324(14):1453-1454. PubMed ID: 32926089
    [No Abstract]   [Full Text] [Related]  

  • 54. Survey of bullous pemphigoid disease in northern Iran.
    Banihashemi M; Zabolinejad N; Vahabi S; Razavi HS
    Int J Dermatol; 2015 Nov; 54(11):1246-9. PubMed ID: 25783773
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eosinophilic, polymorphic, and pruritic eruption associated with radiotherapy (EPPER) mimicking bullous pemphigoid in a patient with anaplastic large cell lymphoma.
    Masuno Y; Matsumura Y; Katoh M; Arakawa A; Kore-Eda S; Ishikawa T; Miyachi Y
    Eur J Dermatol; 2011; 21(3):421-2. PubMed ID: 21524984
    [No Abstract]   [Full Text] [Related]  

  • 56. Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma.
    Hansen I; Gebhardt C; Booken N; Schneider SW
    J Dtsch Dermatol Ges; 2024 Apr; 22(4):587-589. PubMed ID: 38379256
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.
    Moghadam P; Tancrede E; Bouaziz JD; Kallout J; Bedane C; Begon E; Bourgault-Villada I; Calugareanu A; Dereure O; Jendoubi F; Pham-Ledard A; Ingen-Housz-Oro S; Picard-Dahan C; Viguier M; Mahevas T; Jachiet M; Charvet E; Cassius C; Alexandre M; Lepelletier C
    Br J Dermatol; 2023 Jul; 189(2):244-246. PubMed ID: 37155583
    [No Abstract]   [Full Text] [Related]  

  • 58. Toward a practical renaming of bullous pemphigoid and all its variants: cutaneous pemphigoid.
    Borradori L; Joly P
    JAMA Dermatol; 2014 Apr; 150(4):459. PubMed ID: 24718431
    [No Abstract]   [Full Text] [Related]  

  • 59. PD-L1 positive macrophages were increased in a case of pembrolizumab-induced bullous pemphigoid.
    Nakai K; Sato Y; Kubo S; Tsuruta D
    J Dermatol; 2021 Mar; 48(3):e146-e148. PubMed ID: 33439513
    [No Abstract]   [Full Text] [Related]  

  • 60. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
    Russo R; Cozzani E; Gasparini G; Parodi A
    Dermatol Ther; 2020 Jan; 33(1):e13190. PubMed ID: 31863534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.